Monsanto Technology LLC

Immulogic Pharmaceutical Corporation

Merck Patent Gmbh

Revolution Medicines, Inc.

Heska Corporation

Ginkgo Bioworks, Inc.

Other

Warp Drive Bio, Inc.

Jay Paul Morgenstern

Stanislaw Flasinski

James Arthur Baum

Leigh H English

Sara Ann Salvador

Victor M Guzov

Crystal L Dart

James Kevin Roberts

Arlene R Howe

Xiaoran Fu

Thomas Cerruti

Jinling Hung Wang

Andrew W Brauer

Andrzej Konieczny

Gregory Lawrence Verdine

Bruce L Rogers

Brian Roger Bowman

Keith Earl Robison

Mei-chang Kuo

Julia L Greenstein

Richard D Garman

Christine Bizinkauskas

Thomas M Malvar

Catherine Alice Chay

David Joseph Bowen

Uma R Kesanapalli

Ty T Vaughn

Jason S Milligan

Julian F Bond

Mathew Edward Sowa

Irwin J Griffith

Sharon Ann Townson

Dylan Talbot Stiles

Uddhav Kumar Shigdel

Malcolm Morville

Deborah G Rucker

Robert M McCarroll

William P Clinton

David J Chi

Temple F Smith

Christine B Bizinkauskas

Moritz W F Von Rechenberg

Brian M Turczyk

Collin M Stultz

Carlos E Soto

Kevin A Jarrell

Joshua Alan Van Dyke Blodgett

Malcolm L Gefter

Daniel C Gray

Lucy Foulston

Joshua A V Blodgett

Ze'ev Shaked

Thomas J Briner

Andrzej Koniecsny

Joshua AV Blodgett

Thomas A Cerruti

Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.

Chimeric insecticidal proteins toxic or inhibitory to lepidopteran pests

Disclosed herein are nucleotide sequences encoding an insecticidal protein exhibiting Lepidopteran inhibitory activity, as well as novel insecticidal proteins referred to herein as a BCW 001, BCW 002, BCW 003, and BCW toxic protein-containing chimeras and BCW toxin insecticide, transgenic plants expressing the chimeras or the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.

Pesticidal toxin proteins active againstinsects

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.

Compounds that participate in cooperative binding and uses thereof

Disclosed herein are nucleotide sequences encoding an insecticidal protein exhibitinginhibitory activity, as well as novel insecticidal proteins referred to herein as a BCW 001, BCW 002, BCW 003, and BCW toxic protein-containing chimeras and BCW toxin insecticide, transgenic plants expressing the chimeras or the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.

Pesticidal toxin proteins active against lepidopteran insects

The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or &#x3b2;-lactam compounds) with such nucleic acids, vectors, and/or host cells.

Compositions and methods for the production of compounds

Chimeric insecticidal proteins toxic or inhibitory to Lepidopteran pests

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for ex ample through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.

Growing community of inventors

Boston, MA, United States of America

Jay Paul Morgenstern